- Home
- ELBM vs CRDL Comparison
ELBM vs CRDL Comparison
Compare ELBM & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- CRDL
- Stock Information
- Founded
- ELBM 2011
- CRDL 2017
- Country
- ELBM Canada
- CRDL Canada
- Employees
- ELBM N/A
- CRDL N/A
- Industry
- ELBM Industrial Machinery/Components
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELBM Miscellaneous
- CRDL Health Care
- Exchange
- ELBM Nasdaq
- CRDL Nasdaq
- Market Cap
- ELBM 97.4M
- CRDL 90.4M
- IPO Year
- ELBM N/A
- CRDL N/A
- Fundamental
- Price
- ELBM $1.02
- CRDL $1.06
- Analyst Decision
- ELBM Strong Buy
- CRDL Strong Buy
- Analyst Count
- ELBM 2
- CRDL 2
- Target Price
- ELBM $2.20
- CRDL $9.00
- AVG Volume (30 Days)
- ELBM 10.9M
- CRDL 676.5K
- Earning Date
- ELBM 11-14-2025
- CRDL 11-12-2025
- Dividend Yield
- ELBM N/A
- CRDL N/A
- EPS Growth
- ELBM N/A
- CRDL N/A
- EPS
- ELBM N/A
- CRDL N/A
- Revenue
- ELBM N/A
- CRDL N/A
- Revenue This Year
- ELBM N/A
- CRDL N/A
- Revenue Next Year
- ELBM N/A
- CRDL N/A
- P/E Ratio
- ELBM N/A
- CRDL N/A
- Revenue Growth
- ELBM N/A
- CRDL N/A
- 52 Week Low
- ELBM $0.77
- CRDL $0.77
- 52 Week High
- ELBM $8.70
- CRDL $1.98
- Technical
- Relative Strength Index (RSI)
- ELBM 44.50
- CRDL 46.04
- Support Level
- ELBM $0.97
- CRDL $0.98
- Resistance Level
- ELBM $1.15
- CRDL $1.15
- Average True Range (ATR)
- ELBM 0.14
- CRDL 0.05
- MACD
- ELBM -0.06
- CRDL -0.01
- Stochastic Oscillator
- ELBM 13.01
- CRDL 32.54
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.